In Crohn disease (CD), anti–tumor necrosis factor therapies like adalimumab have provided an alternative to long-term corticosteroid therapy and have reduced the need for many patients to have surgical interventions. It has been proposed that early treatment with biologics may lead to better outcomes and fewer complications—like strictures and fistulae—and findings from a recent study support that assertion.
In Crohn disease (CD), anti—tumor necrosis factor therapies like adalimumab have provided an alternative to long-term corticosteroid therapy and have reduced the need for many patients to have surgical interventions. It has been proposed that early treatment with biologics may lead to better outcomes and fewer complications—like strictures and fistulae—and findings from a recent study support that assertion.
The retrospective study was conducted among 157 patients with CD who were treated with adalimumab between 2008 and 2016 at a single center in Italy. The investigators analyzed whether early treatment with adalimumab (within 12 months of diagnosis with CD) improved patient outcomes.
The patients had a mean age of 43.99 years, and 68.15% were men. Most of the patients (91.01%) had received systemic corticosteroids before starting adalimumab, but not all responded to steroid treatment. Seventy-five of the patients had also used other therapies, including infliximab, azathioprine, and antibiotics.
At month 12 after initiating adalimumab, overall, 50.32% of patients achieved clinical remission. A clinical response was observed in 35.03% of patients. Among both those in remission and those with a response, 62.42% did not need steroids, and 37.58% showed mucosal healing.
Among the 80 patients who started adalimumab within 1 year of diagnosis, the clinical remission rate (66.25%) was significantly superior to the remission rate (33.77%) among the 77 patients who started adalimumab more than 1 year from diagnosis (P ≤.001).
Mucosal healing was observed in 53.75% of the early treatment group and in 20.78% of the late treatment group (P <.001), and dose escalation was required for 30.00% of the early treatment group and in 66.23% of the late treatment group (P <.01).
Finally, 7.50% of patients in the early treatment group were classified as nonresponders at the end of follow-up, versus 22.08% of patients in the late treatment group.
Early treatment with adalimumab, write the study’s authors, may improve clinical outcomes by preventing fibrosis from developing by blocking the cascade of events leading to the fibrogenic process. “In light of our data, it is tempting to speculate that early control of gut inflammation is critical to prevent fibrostenotic intestinal injury previously described as a major factor leading to poor patient outcomes,” they write, adding that these data support introducing adalimumab during a “window period” before there are structural alterations to the bowel.
Reference
Mastronardi M, Curlo M, Cavalcanti E, et al. Administration timing is the best clinical outcome predictor for adalimumab administration in CD. Front Med (Lausanne). 2019;6:234. doi: 10.3389/fmed.2019.00234.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.